What are the recommended treatment strategies for beta thalassemia, including transfusion thresholds, iron chelation therapy, and curative options?

Management of Beta-Thalassemia Major

Regular red-cell transfusions combined with iron chelation therapy form the cornerstone of treatment for transfusion-dependent β-thalassemia major, while hematopoietic stem cell transplantation (HSCT) should be offered in the first years of life—preferably before age 14—for patients with an HLA-matched sibling donor, as this provides the only widely available cure with disease-free survival rates of 96% in younger patients. 1

Transfusion Therapy

• Maintain regular red-cell transfusions to sustain adequate hemoglobin levels, suppress ineffective erythropoiesis, and prevent skeletal deformities and growth retardation 1
• Transfusion-dependent thalassemia (TDT) is defined as requiring >8 transfusion events per year in adults aged >16 years 2
• Each unit of blood delivers approximately 200 mg of iron, necessitating lifelong chelation therapy 2

Iron Chelation Therapy

Three chelators are available with proven efficacy:

• Deferiprone shows superior efficacy versus deferoxamine for cardiac protection 2
• Combined deferiprone with deferoxamine demonstrates superiority over deferoxamine alone 2
• Deferasirox is equivalent to deferoxamine in overall efficacy 2

Critical Monitoring Requirements

• Regular assessment of iron burden using cardiac MRI (T2*) and liver iron concentration is essential to prevent iron-related organ damage, particularly cardiac disease which remains the predominant cause of death 2
• Monitor adherence closely, as inadequate iron chelation continues to contribute to preventable morbidity and mortality 3
• Assess for chelator adverse effects and adjust treatment accordingly 3

Common Pitfall

Iron overload develops not only from transfusions but also from increased gastrointestinal iron absorption due to hepcidin suppression, even in non-transfusion-dependent patients 2

Curative Options: HSCT

HSCT represents the definitive cure and should be prioritized in eligible patients:

Timing Is Critical

• Perform HSCT before age 14 years whenever possible—disease-free survival drops from 96% to 74% when delayed beyond this age 1
• Offer transplant in the first years of life, ideally before iron-induced organ complications develop 1

Outcomes with Modern HSCT

• Overall survival: 91% 1
• Disease-free survival: 83% 1
• Transplant-related mortality in young, low-risk patients with matched sibling donors: ≤5% 1

Risk Stratification

Three factors predict HSCT success 1:

1. Age at transplantation (younger is better)
2. Presence and severity of iron-related organ dysfunction
3. Hepatomegaly and liver fibrosis

Eligibility

• Recommend HSCT for patients younger than 14 years with an HLA-matched sibling donor 1
• Allogeneic HSCT from HLA-identical donors yields excellent results in children 4

Emerging Curative Therapies

Gene Therapy

• Betibeglogene autotemcel (beti-cel) is FDA-approved and achieves transfusion independence in the majority of TDT patients across different age groups and genotypes 4, 5
• Lentiviral vector-based gene addition therapy has demonstrated multi-year follow-up data showing sustained efficacy 4
• CRISPR-Cas9 gene editing targeting BCL11A expression achieves high fetal hemoglobin levels, allowing transfusion discontinuation 4

Major Barriers to Gene Therapy Access

• Cost: USD 2.8 million per patient for ZYNTEGLO limits widespread adoption 6
• Risk of secondary hematological malignancies: Complex and multifactorial, not limited to insertional mutagenesis 4
• Commercialization challenges have led to market withdrawal in Europe despite regulatory approval 4

Luspatercept

• This erythroid maturation agent (activin ligand trap) reduces RBC transfusion burden and improves quality of life in TDT patients 5, 7
• Targets ineffective erythropoiesis directly 7

Treatment Algorithm by Clinical Scenario

For Newly Diagnosed Children (<14 years) with Matched Sibling Donor

1. Proceed directly to HSCT evaluation 1
2. Minimize iron accumulation pre-transplant
3. Expect 96% disease-free survival 1

For Patients Without Matched Donor or Age >14 Years

1. Initiate regular transfusion program (>8 events/year) 2
2. Start iron chelation immediately—prefer deferiprone for cardiac protection or combined deferiprone/deferoxamine 2
3. Monitor cardiac T2* MRI and liver iron concentration every 6-12 months 2
4. Consider gene therapy if available and affordable 4, 5
5. Consider luspatercept to reduce transfusion burden 5

For Low-Income Settings

• HSCT remains the only feasible curative option where optimal transfusion and chelation services are unavailable, though access is severely limited 1

Cardiac Complications Prevention

• Cardiac disease is easier and safer to treat at an early stage rather than late stage when mortality risk is high 2
• Heart disease has been the predominant cause of death in β-thalassemia major historically 2
• Tailored chelation treatment focused on cardiac iron removal has contributed to significant reduction in cardiac mortality 2
• Early identification of myocardial siderosis using cardiac MRI T2* allows risk stratification and treatment intensification 2

Long-Term Outcomes

With standardized transfusion protocols and effective iron chelation, patients now routinely survive into the fourth or fifth decade, converting β-thalassemia major from a rapidly fatal childhood disease into a chronic condition 1